Companies sometimes raise big venture capital rounds to invest in equipment, people, and other tools for growth. Other times they do it to provide the business a cash cushion. And sometimes it’s about giving potential customers and partners more confidence in... Read more »
Mark Skinner, the former longtime president of the World Federation of Hemophilia, has had the blood disease on his mind his entire life.
He doesn’t have a choice.
Skinner, 57, was born with a severe form of hemophilia A, meaning he... Read more »
[Updated, 12/13/17, 1:50 p.m. ET. See below.] The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus the more notable market movements. No surprise, there’s a lot... Read more »
Whether you think self-driving cars are the stuff of science fiction or a potentially paradigm-shifting new form of transportation, autonomous vehicles are coming—and the companies developing them are spending big money to make it happen.
A few years ago, industry analysts... Read more »
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too.
The FDA will... Read more »
Rahul Chaturvedi worked for 16 years as a life sciences company executive, but he was also an avid consumer tech fan who chafed at the clunky enterprise apps used in his industry. Spoiled by speedy, user-friendly consumer apps, he also wondered... Read more »
Metacrine, a biotech developing new drugs for treating chronic liver diseases and related metabolic diseases and disorders, said today it has raised $22 million in a Series B financing led by New Enterprise Associates, a new investor.
Proceeds will be... Read more »
How do you disrupt an industry that markets itself as the embodiment of “forever?”
You bring it back to basics, says Lindsay Reinsmith, co-founder of Ada Diamonds, an online retailer of jewelry with lab-made gemstones in San Francisco. “Science is on... Read more »
There’s just one week left before Xconomy’s latest biotech event, “San Diego Life Sciences 2022.” Don’t let the clock run out while you can still save some cash on a ticket.
Next Monday, December 11, we’re taking an inside look at... Read more »
[Corrected, 12/11/17, 1 p.m. ET. See below.] On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data, including trials for lung cancer, heart disease, melanoma, Alzheimer’s disease,... Read more »
Author, investor, and AOL co-founder Steve Case today announced a new $150 million venture fund aimed at pumping investment capital into tech companies in so-called flyover states. Contributing to the fund is an impressive group of some of the most successful... Read more »
The reaction on Wall Street was a little anticlimactic after the FDA approved a new hepatitis B vaccine last month for Berkeley, CA-based Dynavax Technologies (NASDAQ: DVAX).
Many investors sold stock on the news. In the days following the... Read more »
Many of biotech’s biggest stories in 2017 followed the highly anticipated data from clinical studies. There were monumental successes, like the first-ever approval of a genetically modified living cell therapy, the first FDA application for a gene therapy or a... Read more »